Sastasundar: A good deal for ace investor Ashish Kacholia

Sastasundar: A good deal for ace investor Ashish Kacholia

Shares of Sastasundar Ventures jumped 5% in early trade on Tuesday after veteran investor Ashish Kacholia bought 225,000 shares of Sastasundar Ventures at Rs 447 apiece through a bulk deal on the National Stock Exchange. The counter climbed to a high of Rs 466.85 as against the previous close of Rs 444.65 on the National Stock Exchange.
Microsec Vision Trust One sold 2.25 lakh shares at Rs 447 per share on the NSE, the bulk deal data showed.
Kacholia already held 1.04% (3.3 lakh shares) stake in Sastasundar as of September 2021.
Recently, the Walmart-controlled Flipkart announced its entry into the healthcare segment by signing an agreement to acquire a majority stake in Sastasundar Marketplace.

The Kolkata-headquartered online pharmacy owns and operates SastaSundar.com. It offers a digital healthcare and pharmacy platform supported by a network of more than 490 pharmacies and is backed by investors from Japan, namely Mitsubishi Corporation and Rohto Pharmaceuticals.
Founded in 2013 by BL Mittal and Ravi Kant Sharma, SastaSundar—supported by a network of more than 490 offline pharmacies—provides affordable healthcare to its consumers by sourcing original products from authorised sources and delivering them across the country. It uses AI and data analytics to provide personal counselling through its platform.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.